{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:01:24Z","timestamp":1775642484885,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peripheral T\u2010cell lymphoma (PTCL) is a heterogeneous group of lymphomas. Most subtypes are generally associated with a poor prognosis when treated with standard chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study enrolled patients with untreated PTCL who received mitoxantrone hydrochloride liposome (Lipo\u2010MIT) plus cyclophosphamide, vincristine, and prednisone (CMOP) every 4 weeks for six cycles. The study consisted of a 3\u00a0+\u00a03 dose\u2010escalation phase (Lipo\u2010MIT at 12, 15, 18, and 21 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and a specific dose\u2010expansion phase (Lipo\u2010MIT at the recommended phase 2 dose [RP2D]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between December 21, 2020, and November 17, 2022, 38 patients were enrolled. No dose\u2010limiting toxicities were reported, and the RP2D was established at 18 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Grade \u22653 treatment\u2010related adverse events occurred in 33 (86.8%) patients, with the most common being neutrophil count decrease (76.3%) and white\u2010cell count decrease (73.7%). No treatment\u2010related deaths occurred. Among the 35 response\u2010evaluable patients, the independent review committee\u2010assessed complete response rate (CRR) was 54.3% (95% CI, 36.6%\u201371.2%), and the overall response rate (ORR) was 88.6% (95% CI, 73.3%\u201396.8%). For the 17 patients treated at RP2D, the CRR, ORR, median duration of CR, and median duration of response were 64.7% (95% CI, 38.3%\u201385.8%), 94.1% (95% CI, 71.3%\u201399.9%), 28.0 (95% CI, 9.8\u201346.3) months, and 28.0 (95% CI, 4.0\u201352.1) months, respectively. At a median follow\u2010up of 23.8 months, the median progression\u2010free survival was 20.8 (95% CI, 6.1\u201335.5) months, and the median overall survival was not reached. Lipo\u2010MIT exhibited a favorable pharmacokinetics (PK) profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CMOP regimen demonstrates a favorable PK profile, a manageable safety profile, and encouraging preliminary antitumor activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70360","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:49:29Z","timestamp":1774111769000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment\u2010naive peripheral T\u2010cell lymphoma: A multicenter, open\u2010label, single\u2010arm, phase 1b trial"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-2999","authenticated-orcid":false,"given":"Yan","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Head and Neck Tumor Department West China Hospital of Sichuan University  Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanye","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology The Fourth Hospital of Hebei Medical University  Shijiazhuang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Union Hospital Tongji Medical College of Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital  Zhengzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Hospital of China Medical University  Shenyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Lymphoma &amp; Hematology Department The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1431-5372","authenticated-orcid":false,"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Sun Yat\u2010Sen University Cancer Center  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010023\u201001904\u2010w"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280275"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.4558"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015114"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.65258"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev\u2010pathol\u2010020117\u2010043821"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100838\u20105"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv624"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003081"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01815"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(18)32984\u20102"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01687"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010014\u20102523\u20108"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2008.05.019"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.10.023"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35672"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010157899"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569\u2010020\u20100348\u20101"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14763"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920923829"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2013.07.010"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011095"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.05.08"},{"key":"e_1_2_8_26_1","article-title":"Pharmacokinetics, safety profiles and efficacy of liposomal mitoxantrone hydro chloride in patients with relapse\/refractory advanced lymphoma","volume":"11","author":"Hu YOW","year":"2023","journal-title":"Chemo Open Access"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010141752"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.167742"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101160"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(18)30039\u20105"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70360","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70360","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:18:44Z","timestamp":1775639924000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1002\/cncr.70360"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70360","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"2025-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70360"}}